How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Acute Toxicity Test Market
- By Test Type: Oral Toxicity Test, Dermal Toxicity Test, Inhalation Toxicity Test, Injection Toxicity Test, Eye Irritation Test
- By Test Organism: Rodents (Rats, Mice), Aquatic Species (Fish, Daphnia), Avian Species (Chickens), Invertebrates (Bees, Earthworms), Non-Rodent Mammals (Rabbits)
- By End-User: Pharmaceutical Companies, Chemical Manufacturers, Contract Research Organizations (CROs), Academic and Research Institutes, Regulatory Agencies
- By Test Methodology: In Vivo Testing, In Vitro Testing, Computational Toxicology (In Silico), Alternative Testing Methods
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Oral Toxicity Test leads By Test Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.168 →
- 11 Company Profiles 17 players: SWOT & benchmarking p.176 →
Full report · locked preview
Everything inside the Acute Toxicity Test Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Test Type 5
Test Organism 5
End-User 5
Test Methodology 4
Companies profiled
Charles River Laboratories International Inc.
Covance Inc. (LabCorp)
Eurofins Scientific
Envigo RMS (now part of Labcorp)
WuXi AppTec
Piramal Pharma Solutions
ICON plc
SGS SA
QPS Holdings
LLC
Toxikon Corporation
NAMSA
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Charles River Laboratories International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Covance Inc. (LabCorp)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Eurofins Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Envigo RMS (now part of Labcorp)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →WuXi AppTec
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Piramal Pharma Solutions
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →ICON plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →SGS SA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →QPS Holdings
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →LLC
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Toxikon Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →NAMSA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →MPI Research (now part of Charles River Laboratories)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →BioReliance (a Merck KGaA company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Frontage Laboratories Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inotiv
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$10,023M by 2033 · 8.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Oral Toxicity Test48.4
- Dermal Toxicity Test14.6
- Inhalation Toxicity Test11.5
- Injection Toxicity Test14.7
- Eye Irritation Test10.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,783M → $3,509M · 8.8%
Europe$1,243M → $2,101M · 6.8%
Asia Pacific$1,135M → $1,990M · 7.3%
Latin America$702.4M → $1,411M · 9.1%
Middle East and Africa$540.3M → $1,050M · 8.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.992026
7.992027
8.012028
8.012029
8.042030
8.042031
8.062032
8.072033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Charles River Laboratories International Inc.23.5
- Covance Inc. (LabCorp)17.5
- Eurofins Scientific7.0
- Envigo RMS (now part of Labcorp)11.2
- WuXi AppTec8.2
- Piramal Pharma Solutions4.7
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Test Type33.6%
Test Organism13.9%
End-User31.4%
Test Methodology21.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.9
- Europe20.9
- Asia Pacific19.8
- Latin America14.0
- Middle East and Africa10.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | 82 | 76 | 91 | 76 | 89 | 88 | 84 |
| Covance Inc. (LabCorp) | 74 | 69 | 84 | 68 | 90 | 91 | 79 |
| Eurofins Scientific | 75 | 75 | 70 | 81 | 70 | 81 | 75 |
| Envigo RMS (now part of Labcorp) | 62 | 60 | 77 | 67 | 82 | 68 | 69 |
| WuXi AppTec | 73 | 54 | 75 | 75 | 70 | 74 | 70 |
| Piramal Pharma Solutions | 54 | 69 | 50 | 61 | 61 | 56 | 59 |
| ICON plc | 58 | 52 | 44 | 51 | 46 | 62 | 52 |
| SGS SA | 58 | 59 | 49 | 55 | 39 | 44 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Charles River Laboratories International Inc.
- Covance Inc. (LabCorp)
- Eurofins Scientific
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | ◐ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Covance Inc. (LabCorp) | − | ✓ | ✓ | ◐ | ✓ | ◐ |
| Eurofins Scientific | ◐ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Envigo RMS (now part of Labcorp) | − | − | ✓ | − | ✓ | ✓ |
| WuXi AppTec | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Piramal Pharma Solutions | − | ◐ | ◐ | − | ◐ | ◐ |
| ICON plc | ◐ | − | − | − | ◐ | ◐ |
| SGS SA | ◐ | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Charles River Laboratories International Inc.84
2Covance Inc. (LabCorp)79
3Eurofins Scientific75
4WuXi AppTec70
5Envigo RMS (now part of Labcorp)69
6Piramal Pharma Solutions59
7ICON plc52
8SGS SA51
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Charles River Laboratories International Inc.Covance Inc. (LabCorp)
Challenger3
Strong scale, closing on the leaders.
Eurofins ScientificEnvigo RMS (now part of Labcorp)WuXi AppTec
Contender1
Focused players with pockets of strength.
Piramal Pharma Solutions
Niche2
Specialists in a single segment or region.
ICON plcSGS SA
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Test Type in North America, then scale across Acute Toxicity Test Market — a $847M beachhead inside a $12.1B market.
Beachhead (SOM)$847Mobtainable near-term
Serviceable (SAM)$4.84Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Oral Toxicity Test
Best fit — highest urgency & budget in Test Type.
Economic buyer78 fit
Dermal Toxicity Test
Strong fit — clear ROI and a fast path to value.
End user68 fit
Inhalation Toxicity Test
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Test Organism & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End-User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel26%
Digital / self-serve22%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Test Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Acute Toxicity Test Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified21%
Evaluation12%
Closed-won5%
$15.0KCAC
$69KLTV
4.6:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Acute Toxicity Test Market is a durable-growth opportunity — $2.36B by 2033, compounding at 8.3%.
TAM · 2025$1.25Btoday
TAM · 2033$2.36Bforecast
CAGR8.3%2027–2033
Cumulative$15.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.36BTotal addressable market
SAM$982MServiceable available market
SOM$206MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.3% CAGR
Demand compounds through 2033, outpacing GDP across Test Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.36BLarge & growingTAM by 2033 at 8.3% CAGR
$982MServiceable nowreachable with today’s model
$206MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.84BBear5.4% CAGR
$2.36BBase8.3% CAGR
$3.02BBull11.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Test Organism optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Acute Toxicity Test Market — a $2.02B market by 2033. Plan: grow share from 9.5% to 17.3%.
Market size · 2033$2.02Btotal addressable
Market CAGR10.8%2027–2033
Target share17.3%from 9.5% today
Revenue ambition$350Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.5% | 17.3% | At risk |
| Revenue | $182M | $350M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 34.2% | 43.9% | At risk |
| Customer retention | 86.6% | 92.1% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Test Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Test Organism capability
A defensible second engine — invest in Test Organism to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Test Organism
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $38M capacity & capability investment
- Greenlight bolt-on M&A in Test Organism
- Authorise North America expansion plan
- Fund R&D program for Test Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Acute Toxicity Test Market conversation — a $6.14B market you can size, segment and defend in minutes.
Market size · 2033$6.14Btotal opportunity
Growth7.8%CAGR to 2033
Addressable buyers1,300+accounts in scope
Typical ROI6.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Type
Goal Grow share in Test Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.1×return on cost, year one
< 4 mopayback period
$60K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Charles River Laboratories International Inc.Covance Inc. (LabCorp)Eurofins ScientificEnvigo RMS (now part of Labcorp)WuXi AppTecPiramal Pharma SolutionsICON plcSGS SA+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Acute Toxicity Test Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Acute Toxicity Test Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Acute Surgical Mechanical Circulatory Support System Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportAcute Sinusitis Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportAcute Respiratory Distress Syndrome Ventilation Treatment Device Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportAcute Respiratory Distress Syndrome Treatment Device Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportPlastic Surgery Software Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportAcute Respiratory Distress Syndrome Device Market
Market size, share, segmentation and regional forecast.
$380M market · 2025 base year
View reportAcute Respiratory Distress Syndrome (ARDS) Treatment Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportAcute Pain Management Services Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportShort Term Health Insurance Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportAcute Myeloid Leukemia Biomarker Detection Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportAcute Myeloid Leukemia (AML) Biomarker Testing Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportAcute Migraine Medications Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.